ImmunoGen (IMGN) stock price, revenue, and financials

ImmunoGen market cap is $843 m, and annual revenue was $132.3 m in FY 2020

$843 M

IMGN Mkt cap, 13-May-2022

$15.7 M

ImmunoGen Revenue Q1, 2021
ImmunoGen Net income (Q1, 2021)-34.1 M
ImmunoGen EBIT (Q1, 2021)-28.9 M
ImmunoGen Cash, 31-Mar-2021283.1 M
ImmunoGen EV583 M
Get notified regarding key financial metrics and revenue changes at ImmunoGenLearn more
Banner background

ImmunoGen Revenue Breakdown

Embed Graph

ImmunoGen revenue breakdown by business segment: 51.8% from Non-Cash Royalty Revenue, 48.2% from License and Milestone Fees and 0.0% from Other

ImmunoGen Income Statement

Annual

USDFY, 2018FY, 2019FY, 2020

Revenue

53.4m82.3m132.3m

Revenue growth, %

54%61%

R&D expense

174.5m114.5m114.6m

General and administrative expense

36.7m38.5m38.6m

Operating expense total

214.9m174.4m154.7m

EBIT

(161.4m)(92.2m)(22.4m)

EBIT margin, %

(302%)(112%)(17%)

Investment income

4.2m4.4m729.0k

Net Income

(168.8m)(104.1m)(44.4m)

EPS

(1.2)(0.7)(0.2)

ImmunoGen Balance Sheet

Annual

USDFY, 2018FY, 2019FY, 2020

Cash

262.3m176.2m293.9m

Accounts Receivable

1.7m7.5m35.0k

Prepaid Expenses

4.5m5.4m7.9m

Current Assets

278.8m208.9m324.3m

PP&E

12.9m7.0m5.8m

Total Assets

295.4m235.3m355.1m

Accounts Payable

11.4m9.9m9.5m

Short-term debt

3.0m5.2m

Current Liabilities

70.7m77.4m122.3m

Long-term debt

2.1m23.9m18.7m

Total Debt

2.1m26.8m23.9m

Total Liabilities

284.4m311.4m265.5m

Common Stock

1.5m1.5m2.0m

Additional Paid-in Capital

1.2b1.2b1.4b

Retained Earnings

(1.2b)(1.3b)(1.3b)

Total Equity

11.0m(76.1m)89.6m

Debt to Equity Ratio

0.2 x-0.4 x0.3 x

Debt to Assets Ratio

0 x0.1 x0.1 x

Financial Leverage

26.9 x-3.1 x4 x

ImmunoGen Cash Flow

Annual

USDFY, 2018FY, 2019FY, 2020

Net Income

(168.8m)(104.1m)(44.4m)

Depreciation and Amortization

7.4m4.0m2.1m

Accounts Receivable

948.0k(5.8m)7.5m

Inventories

1.0m

Accounts Payable

2.7m(1.0m)(819.0k)

Cash From Operating Activities

(166.4m)(88.4m)(78.6m)

Purchases of PP&E

(5.2m)(2.8m)(917.0k)

Cash From Investing Activities

(5.2m)(533.0k)509.0k

Cash From Financing Activities

166.8m2.9m195.7m

Net Change in Cash

(4.9m)(86.0m)117.6m

Interest Paid

95.0k95.0k95.0k

Quarterly

USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(43.8m)(87.2m)(108.9m)(29.1m)(53.4m)(75.8m)(34.1m)

Depreciation and Amortization

1.2m2.4m3.3m529.0k1.0m1.6m551.0k

Accounts Receivable

1.5m1.7m1.6m7.4m7.2m2.5m(58.0k)

Accounts Payable

(2.7m)(3.2m)(3.8m)(649.0k)2.2m(1.0m)3.8m

Cash From Operating Activities

10.2m(20.8m)(55.8m)(28.3m)(56.5m)(87.2m)(44.6m)

Purchases of PP&E

(2.1m)(2.4m)(2.8m)(21.0k)(44.0k)(815.0k)(893.0k)

Cash From Investing Activities

(2.1m)(2.4m)(2.8m)1.4m1.4m611.0k(893.0k)

Cash From Financing Activities

68.0k738.0k811.0k98.0m98.4m98.5m34.8m

Net Change in Cash

8.1m(22.4m)(57.8m)71.1m43.3m12.0m(10.7m)

ImmunoGen Ratios

USDFY, 2018

Revenue/Employee

180.6k

Debt/Equity

0.2 x

Financial Leverage

26.9 x

ImmunoGen Operating Metrics

FY, 2018FY, 2019FY, 2020

Patent Applications

600650600

Patents Issued

1 k1.3 k1.4 k

ImmunoGen Employee Rating

3.473 votes
Culture & Values
3.1
Work/Life Balance
3.7
Senior Management
2.5
Salary & Benefits
3.8
Career Opportunities
2.8
Source